###begin article-title 0
###xml 29 41 29 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BSCL2/Seipin</italic>
###xml 4 9 <span type="species:ncbi:9606">Human</span>
The Human Lipodystrophy Gene BSCL2/Seipin May Be Essential for Normal Adipocyte Differentiation
###end article-title 0
###begin p 1
###xml 42 57 42 57 <email xmlns:xlink="http://www.w3.org/1999/xlink">jjr30@cam.ac.uk</email>
Corresponding author: Justin J. Rochford, jjr30@cam.ac.uk
###end p 1
###begin p 2
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See  for details.
###end p 2
###begin p 3
###xml 0 10 0 10 <bold xmlns:xlink="http://www.w3.org/1999/xlink">OBJECTIVE&#8212;</bold>
###xml 184 189 184 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BSCL2</italic>
###xml 463 468 463 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BSCL2</italic>
OBJECTIVE-Berardinelli-Seip congenital lipodystrophy type 2 (BSCL2) is a recessive disorder featuring near complete absence of adipose tissue. Remarkably, although the causative gene, BSCL2, has been known for several years, its molecular function and its role in adipose tissue development have not been elucidated. Therefore, we examined whether BSCL2 is involved in the regulation of adipocyte differentiation and the mechanism whereby pathogenic mutations in BSCL2 cause lipodystrophy.
###end p 3
###begin p 4
###xml 0 28 0 28 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RESEARCH DESIGN AND METHODS&#8212;</bold>
###xml 62 67 62 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BSCL2</italic>
###xml 162 167 162 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BSCL2</italic>
RESEARCH DESIGN AND METHODS-Following the characterization of BSCL2 expression in developing adipocytes, C3H10T1/2 mesenchymal stem cells were generated in which BSCL2 expression was knocked down using short hairpin RNA (shRNA). These cells were used to investigate whether BSCL2 is required for adipogenesis. BSCL2 constructs harboring pathogenic mutations known to cause lipodystrophy were also generated and characterized.
###end p 4
###begin p 5
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RESULTS&#8212;</bold>
###xml 8 13 8 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BSCL2</italic>
###xml 101 106 101 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BSCL2</italic>
###xml 577 582 565 570 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lipin</italic>
###xml 582 583 570 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1</italic>
###xml 589 594 577 582 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DGAT2</italic>
###xml 702 707 690 695 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BSCL2</italic>
###xml 750 755 738 743 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A212P</italic>
RESULTS-BSCL2 expression was strongly induced during adipocyte differentiation, and the induction of BSCL2 expression was essential for adipogenesis to occur. The initial induction of key adipogenic transcription factors, including peroxisome proliferator-activated receptor (PPAR)gamma and CAAT/enhancer-binding protein-alpha, was preserved in cells lacking BSCL2. However, the expression of these critical factors was not sustained, suggesting that the activity of PPARgamma was impaired. Moreover, expression of key genes mediating triglyceride synthesis, including AGPAT2, lipin1, and DGAT2, was persistently reduced and lipid accumulation was inhibited. Analysis of pathogenic missense mutants of BSCL2 revealed that the amino acid substitution A212P causes aberrant targeting of BSCL2 within the cell, suggesting that subcellular localization of BSCL2 may be critical to its function.
###end p 5
###begin p 6
###xml 0 12 0 12 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CONCLUSIONS&#8212;</bold>
CONCLUSIONS-This study demonstrates that BSCL2 is an essential, cell-autonomous regulator of adipogenesis.
###end p 6
###begin p 7
Published ahead of print at  on 5 May 2008.
###end p 7
###begin p 8
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
###end p 8
###begin p 9
###xml 299 300 299 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
Metabolic homeostasis requires the ability to expand adipose tissue appropriately, as illustrated by lipodystrophy, in which inability to increase adipose tissue mass commonly leads to severe hypertriglyceridemia, insulin resistance, and diabetes due to ectopic lipid accumulation in other tissues (1). Identifying the key genes and regulatory processes involved in adipocyte development is likely to enhance understanding of both pathologically increased and decreased adipose mass.
###end p 9
###begin p 10
###xml 171 176 171 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARG</italic>
###xml 178 182 178 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AKT2</italic>
###xml 235 241 235 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AGPAT2</italic>
###xml 244 245 244 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 276 280 276 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LMNA</italic>
###xml 285 291 285 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ZMPSTE</italic>
###xml 328 332 328 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LMNA</italic>
###xml 399 400 399 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r2">2</xref>
###xml 438 443 438 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BSCL2</italic>
###xml 589 590 589 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r3">3</xref>
###xml 591 592 591 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
###xml 674 679 674 679 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BSCL2</italic>
###xml 750 751 750 751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r5">5</xref>
###xml 935 936 935 936 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r3">3</xref>
###xml 937 938 937 938 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r6">6</xref>
###xml 1024 1029 1024 1029 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BSCL2</italic>
###xml 1042 1049 1042 1049 <italic xmlns:xlink="http://www.w3.org/1999/xlink">YLR404W</italic>
###xml 1103 1108 1103 1108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BSCL2</italic>
###xml 1128 1129 1128 1129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r7">7</xref>
###xml 1286 1291 1286 1291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BSCL2</italic>
###xml 37 42 <span type="species:ncbi:9606">human</span>
###xml 1006 1011 <span type="species:ncbi:4932">yeast</span>
###xml 1119 1126 <span type="species:ncbi:9606">patient</span>
Several different genetic defects in human lipodystrophy have been identified. Some affect genes with a well-established role in adipogenesis or lipid metabolism, such as PPARG, AKT2, and l-acylglycerol-3-phosphate 0-acyltransferate2 (AGPAT2) (1). The role of others, such as LMNA and ZMPSTE, is less clear, although defects in LMNA do perturb adipocyte differentiation in a cell-autonomous manner (2). In contrast, although mutations in BSCL2 produce more severe adipose tissue loss than any of these other genetic defects, very little is known about the underlying pathogenic mechanism (3,4). The global adipose deficit in affected individuals has led to speculation that BSCL2 is involved in stem cell determination toward the adipogenic lineage (5). An alternative suggestion, based on reports of relatively high expression in the central nervous system, is that lipodystrophy results from loss of a key central function of BSCL2 (3-6). A recent study has described abnormal lipid droplet formation in yeast lacking the BSCL2 orthologue, YLR404W, and a similar defect in fibroblasts isolated from a BSCL2-deficient patient (7). However, the localization and function of BSCL2 in differentiating or mature adipocytes remains to be elucidated, as does the molecular mechanism whereby BSCL2 mutations cause lipodystrophy.
###end p 10
###begin title 11
RESEARCH DESIGN AND METHODS
###end title 11
###begin title 12
Tissue analysis.
###end title 12
###begin p 13
###xml 181 182 181 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r8">8</xref>
###xml 279 280 279 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
###xml 51 55 <span type="species:ncbi:10090">mice</span>
###xml 185 191 <span type="species:ncbi:10090">Murine</span>
###xml 196 201 <span type="species:ncbi:9606">human</span>
Tissues were isolated from 10-week-old male C57Bl6 mice, and RNA was isolated using STAT-60 (AMS Biotechnology). RNA was quantified and reverse transcribed as previously described (8). Murine and human adipose tissue were isolated and fractionated, also as previously described (9).
###end p 13
###begin title 14
Cell culture.
###end title 14
###begin p 15
###xml 626 627 623 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r8">8</xref>
###xml 732 733 729 730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r8">8</xref>
###xml 107 111 <span type="species:ncbi:9913">calf</span>
###xml 483 488 <span type="species:ncbi:9606">Human</span>
###xml 493 499 <span type="species:ncbi:10090">murine</span>
C3H10T1/2 mesenchymal cells were grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% newborn calf serum. Two days after reaching confluence, cultures were induced to differentiate in DMEM (5 mmol/l glucose) containing 10% FCS, supplemented with 1 mumol/l insulin, 0.5 mmol/l 3-isobutyl-1-methyl-xanthine, and 1 mumol/l dexamethasone for 2 days and then supplemented with 1 mumol/l insulin alone for 2 days. After 4 days, cells were cultured in DMEM containing 10% FCS. Human and murine cells from the stromovascular fraction of adipose tissue were prepared, cultured, and differentiated as previously described (8). RNA isolation, reverse transcription, and real-time PCR were performed, also as previously described (8). RNA was isolated and reverse transcribed from transiently transfected cells using the Qantitect Reverse Transcription kit (Qiagen).
###end p 15
###begin p 16
###xml 127 129 127 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r10">10</xref>
###xml 306 307 306 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r8">8</xref>
###xml 4 10 <span type="species:ncbi:10090">murine</span>
E14 murine embryonic stem cells culture, embryoid body formation, and adherent culture were performed as previously described (10). Adipogenesis was induced using the same regimen as for C3H10T1/2 cells and 3T3-L1 adipocytes. Oil red O staining of lipid accumulation was performed as previously described (8).
###end p 16
###begin title 17
Retrovirus-mediated short hairpin RNA knockdown.
###end title 17
###begin p 18
###xml 401 402 401 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
Two short hairpin RNA (shRNA) sequences targeting BSCL2 were designed and cloned into the RNAi-Ready pSIREN-RetroQ vector (BD Biosciences Clontech). Retroviral packaging BOSC-HEK293 cells were transfected with both these constructs and a control shRNA vector to generate retroviruses to infect C3H10T1/2 cells. Virus collection, preparation, and cell infection were performed as previously described (9).
###end p 18
###begin title 19
Western blotting and immunofluorescence.
###end title 19
###begin p 20
###xml 55 56 55 56 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r8">8</xref>
Protein samples were prepared as previously described (8). A total of 30 mug protein was denatured and analyzed by Western blotting, using antibodies to C/EBPbeta, C/EBPdelta, and ETO (Santa Cruz Biotechnology); myc (4G10, UBI); and calnexin (AbCam). For immunofluorescence studies, cells were grown on glass coverslips, fixed in 10% formalin, permeablized with 0.5% saponin, blocked with 1% BSA, and probed with antibodies diluted in 1% BSA. Coverslips were mounted in ProLong Gold medium (Invitrogen) and analyzed on a Zeiss 510 Meta confocal microscope.
###end p 20
###begin title 21
RESULTS
###end title 21
###begin p 22
###xml 142 143 142 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
###xml 193 195 193 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
###xml 409 410 409 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 403 410 403 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>A</italic></xref>
###xml 516 521 504 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BSCL2</italic>
###xml 256 261 <span type="species:ncbi:10090">mouse</span>
Previous studies reporting the tissue distribution of BSCL2, as assessed by Northern blotting, have reported highest expression in the brain (4) or did not determine adipose tissue expression (11). Quantification of BSCL2 using real-time PCR in a range of mouse tissues demonstrated that expression was highest in subcutaneous and epididymal white adipose depots and interscapular brown adipose tissue (Fig. 1A). Expression in whole brain was approximately20-35% that in adipose tissue, leading us to speculate that BSCL2 mutations may cause lipodystrophy via direct effects in adipose tissue.
###end p 22
###begin p 23
###xml 110 115 110 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BSCL2</italic>
###xml 243 248 243 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BSCL2</italic>
###xml 366 367 366 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 360 367 360 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>B</italic></xref>
###xml 457 458 453 454 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 553 558 545 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BSCL2</italic>
###xml 743 748 735 740 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BSCL2</italic>
###xml 822 823 814 815 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 816 823 808 815 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>C</italic></xref>
###xml 892 893 880 881 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 967 972 951 956 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BSCL2</italic>
###xml 1198 1199 1182 1183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1192 1199 1176 1183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>D</italic></xref>
###xml 1218 1219 1202 1203 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1212 1219 1196 1203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>E</italic></xref>
###xml 1436 1437 1420 1421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1430 1437 1414 1421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>F</italic></xref>
###xml 1456 1457 1440 1441 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 1450 1457 1434 1441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>G</italic></xref>
###xml 1518 1523 1502 1507 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BSCL2</italic>
###xml 119 125 <span type="species:ncbi:10090">murine</span>
###xml 1185 1190 <span type="species:ncbi:10090">mouse</span>
###xml 1205 1210 <span type="species:ncbi:9606">human</span>
###xml 1423 1428 <span type="species:ncbi:10090">mouse</span>
###xml 1443 1448 <span type="species:ncbi:9606">human</span>
To examine the earliest stages of cell commitment to the adipocyte lineage, we investigated the expression of BSCL2 in murine embryonic stem cell embryoid bodies during differentiation to adipocytes. Treatment with adipogenic medium increased BSCL2 expression in these cells within 24 h, and expression continued to rise as the number of adipocytes increased (Fig. 1B). The time course of induction was similar to that of the key adipocyte markers PPARgamma2 and C/EBPalpha (Figs. S1A and B [available in an online appendix at ]), suggesting a role for BSCL2 in terminal adipocyte differentiation rather than early stem cell commitment. Consistent with this finding, adipogenic induction of C3H10T1/2 mesenchymal cells significantly increased BSCL2 expression, apparent after 24 h and strongly induced after 3 days (Fig. 1C). Again, this pattern of expression was similar to that of PPARgamma2 and C/EBPalpha (Fig. S1C and D). A similar, albeit delayed, induction of BSCL2 expression also occurs in differentiating 3T3-L1 preadipocytes (Fig. S1E), with a transient additional peak at day 8 of differentiation. BSCL2 mRNA expression was also induced in differentiating isolated primary mouse (Fig. 1D) and human (Fig. 1E) preadipocytes, remaining raised in the mature adipocytes. Moreover, BSCL2 mRNA was most abundant in the mature adipocyte rather than in stem cell/preadipocyte-containing stromovascular fraction of both mouse (Fig. 1F) and human (Fig. 1G) adipose tissue. These data collectively suggest a role for BSCL2 in developing adipocytes rather than in preadipocytes or stem cells.
###end p 23
###begin p 24
###xml 117 119 117 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
###xml 120 122 120 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r12">12</xref>
###xml 190 192 190 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r13">13</xref>
###xml 417 418 417 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 411 418 411 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>H</italic></xref>
Previous studies have demonstrated that BSCL2 is localized in the endoplasmic reticulum in nonadipogenic cell lines (11,12) and that BSCL2 is inserted in the endoplasmic reticulum membrane (13). Next, we generated C3H10T1/2 cells stably expressing myc-tagged BSCL2. Following differentiation to adipocytes, BSCL2 was found to be also mainly colocalized with the endoplasmic reticulum membrane protein calnexin (Fig. 1H). Similar colocalization was also observed with the endoplasmic reticulum marker calreticulin (data not shown), demonstrating that the majority of BSCL2 is found in this compartment in adipocytes.
###end p 24
###begin p 25
###xml 231 236 231 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BSCL2</italic>
###xml 244 245 244 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 238 245 238 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>A</italic></xref>
###xml 357 358 357 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 351 358 351 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>B</italic></xref>
###xml 443 444 435 436 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 455 456 443 444 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 524 525 512 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 518 525 506 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>C</italic></xref>
###xml 671 672 659 660 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 665 672 653 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>D</italic></xref>
To test the importance of BSCL2 in developing adipocytes, we generated two C3H10T1/2 cell lines stably expressing shRNA species targeting BSCL2. Real-time PCR revealed that both BSCL2 shRNAs effectively inhibited the expression of BSCL2 (Fig. 2A). Following differentiation for 8 days, lipid accumulation was severely impaired in cells lacking BSCL2 (Fig. 2B), as was the induction of the adipogenic transcription factors C/EBPalpha, PPARgamma1, PPARgamma2, and sterol regulatory element binding protein-1c (SREBP1c) (Fig. 2C). These cells also had significantly reduced expression of GLUT4, diacylglycerol O-acyltransferase 2 (DGAT2), lipoprotein lipase, and aP2 (Fig. 2D), demonstrating that the induction of BSCL2 is important for normal adipogenesis.
###end p 25
###begin p 26
###xml 228 230 213 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r14">14</xref>
###xml 375 376 353 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 381 382 359 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 368 382 346 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Figs. 3<italic>A</italic> and <italic>B</italic></xref>
###xml 417 418 395 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 411 418 389 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>C</italic></xref>
###xml 518 519 493 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
###xml 568 569 543 544 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 562 569 537 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>C</italic></xref>
###xml 632 633 599 600 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 668 669 635 636 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 662 669 629 636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>C</italic></xref>
###xml 754 759 721 726 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BSCL2</italic>
###xml 778 779 745 746 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 784 785 751 752 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 772 785 739 752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>D</italic> and <italic>E</italic></xref>
###xml 921 922 888 889 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 915 922 882 889 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>F</italic></xref>
###xml 1003 1004 970 971 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 997 1004 964 971 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>G</italic></xref>
###xml 1020 1021 987 988 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 1014 1021 981 988 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>H</italic></xref>
###xml 1047 1048 1011 1012 <italic xmlns:xlink="http://www.w3.org/1999/xlink">I</italic>
###xml 1041 1048 1005 1012 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>I</italic></xref>
The induction and activation of C/EBPbeta and C/EBPdelta are the best-characterized early events in adipogenesis and are critical for the subsequent induction of the central regulators of this process, C/EBPalpha and PPARgamma (14). When BSCL2 knockdown cells were induced to differentiate for various times up to 72 h, the induction of C/EBPbeta and C/EBPdelta mRNA (Figs. 3A and B, respectively) and protein (Fig. 3C) was equivalent to that in control cells. The rapid suppression of ETO, an inhibitor of C/EBPbeta (9), was also normal in cells lacking BSCL2 (Fig. 3C). Despite the decreased expression of C/EBPalpha and PPARgamma2 mRNAs at later time points (Fig. 2C), the early induction of these factors was also not consistently reduced by loss of BSCL2 expression (Fig. 3D and E). In contrast, the expression of RNA encoding SREBP1c was dramatically decreased in cells lacking BSCL2 at the same time points (Fig. 3F), as was the expression of key enzymes of triglyceride synthesis, AGPAT2 (Fig. 3G), DGAT2 (Fig. 3H), and lipin 1beta (Fig. 3I).
###end p 26
###begin p 27
###xml 109 114 109 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BSCL2</italic>
###xml 195 200 195 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BSCL2</italic>
###xml 272 273 272 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r6">6</xref>
###xml 620 621 620 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
###xml 622 624 622 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r15">15</xref>
###xml 765 766 765 766 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
###xml 1021 1022 1021 1022 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 1015 1022 1015 1022 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>A</italic></xref>
###xml 1185 1186 1185 1186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1179 1186 1179 1186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>B</italic></xref>
###xml 1431 1433 1431 1433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r12">12</xref>
###xml 1772 1773 1772 1773 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1766 1773 1766 1773 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>C</italic></xref>
###xml 863 868 <span type="species:ncbi:9606">human</span>
###xml 900 905 <span type="species:ncbi:9606">human</span>
###xml 925 931 <span type="species:ncbi:10090">murine</span>
Having examined how BSCL2 loss results in a failure of adipogenesis, we examined how pathogenic mutations in BSCL2 may result in the loss of its functional activity. The majority of mutations in BSCL2 causing lipodystrophy generate very short or mostly nonsense proteins (6). This, together with the recessive inheritance pattern, indicates that complete loss of BSCL2 function is required for the development of lipodystrophy. The longest reported premature stop mutation, R275X, is truncated just after the second transmembrane domain, resulting in a predicted protein lacking only the COOH-terminal cytoplasmic tail (4,15). In addition, one lipodystrophy-associated missense mutation has been described, causing substitution of alanine at codon 212 for proline (4). Cells were transiently transfected with constructs encoding either wild-type, R275X, or A212P human BSCL2. Real-time PCR detecting human BSCL2 mRNA in this murine cell line revealed similar transcript levels of wild-type, R275X, and A212P BSCL2 (Fig. 4A). When lysates from identically treated cells were Western blotted for the transfected proteins, BSCL2 protein appeared as a high-molecular weight complex (Fig. 4B). The severely impaired mobility of BSCL2 on SDS-PAGE may result from aggregation due to hydrophobicity of this transmembrane protein and is consistent with previous studies in which the majority of BSCL2 runs at a molecular weight of 250 kDa (12). While both wild-type and A212P proteins were clearly detectable, the R275X protein was not, strongly suggesting that the protein is either rapidly degraded or not translated. When assessed by immunofluorescence, we found that, unlike wild-type BSCL2, a substantial proportion of A212P-BSCL2 was localized to the nuclear envelope (Fig. 4C). Consistent with our Western blot data, R275X-BSCL2 was undetectable by immunofluorescence (data not shown).
###end p 27
###begin title 28
DISCUSSION
###end title 28
###begin p 29
###xml 123 128 123 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BSCL2</italic>
###xml 278 279 278 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r7">7</xref>
We show that BSCL2 expression is critical for normal adipogenesis to occur in vitro. The recent demonstration that loss of BSCL2 causes a defect of lipid droplet morphology led the authors to suggest that defective lipid droplet formation is the primary cause of BSCL2 disease (7). We show that cells lacking BSCL2 fail to induce the expression of SREBP1c and the lipogenic enzymes AGPAT2, DGAT2, and lipin 1. This is evident within 24 h of the induction of adipogenesis, before lipid droplets usually form in these cells. Thus, we propose that a failure to induce adipogenic transcriptional events makes a major contribution to the development of this phenotype.
###end p 29
###begin p 30
###xml 48 53 44 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BSCL2</italic>
###xml 239 241 235 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r16">16</xref>
###xml 242 244 238 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r18">18</xref>
###xml 368 371 364 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">fld</italic>
###xml 379 381 375 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r19">19</xref>
###xml 382 384 378 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r20">20</xref>
###xml 443 445 439 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r21">21</xref>
###xml 295 301 <span type="species:ncbi:9606">humans</span>
###xml 372 377 <span type="species:ncbi:10090">mouse</span>
###xml 413 417 <span type="species:ncbi:10090">mice</span>
The failure to maintain PPARgamma expression in BSCL2 knockdown cells during the later stages of adipogenesis is consistent with reports that loss of either AGPAT2 or lipin 1 inhibits adipogenic gene expression and triglyceride synthesis (16-18). Loss of AGPAT2 activity causes lipodystrophy in humans (BSCL type 1), and lipin 1 disruption causes lipodystrophy in the fld mouse (19,20). Moreover, DGAT2-deficient mice suffer severe lipopenia (21). Our data strongly suggest that individuals lacking BSCL2 may fail to induce the expression of these key lipogenic enzymes during adipogenesis in vivo, which may explain a phenotype more severe than that associated with loss of AGPAT2 alone.
###end p 30
###begin p 31
###xml 252 254 248 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r14">14</xref>
###xml 255 257 251 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r22">22</xref>
###xml 258 260 254 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r23">23</xref>
###xml 437 443 418 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3</xref>
Failure to induce SREBP1c expression in cells lacking BSCL2 may compound, or perhaps cause, these gene-expression changes. SREBP1c both directly activates transcription of adipogenic genes and enhances production of an endogenous ligand for PPARgamma (14,22,23). The early induction of PPARgamma and C/EBPalpha in BSCL2 knockdown cells is believed to be driven largely by C/EBPbeta and C/EBPdelta, which are unaffected by loss of BSCL2 (Fig. 3). However, PPARgamma normally acts to sustain the expression of PPARgamma and C/EBPalpha in the maturing adipocyte. Hence, loss of SREBP1c-dependent PPARgamma ligand production may contribute to decreased PPARgamma and C/EBPalpha expression in maturing adipocytes lacking BSCL2.
###end p 31
###begin p 32
###xml 255 260 255 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BSCL2</italic>
Our data also give novel insight into the mechanism linking two BSCL2 mutants to generalized lipodystrophy. First, the truncated R275X protein is not expressed in cells, suggesting that individuals homozygous for this mutation may be effectively null for BSCL2 expression. Second, the A212P mutant of BSCL2 exhibits aberrant accumulation in the nuclear envelope. The failure of this mutant to support adipose tissue formation in vivo strongly implies that it is functionally inactive. Given the critical importance of this residue, this mutant may be particularly useful in future mechanistic studies of BSCL2 function.
###end p 32
###begin p 33
###xml 182 187 182 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BSCL2</italic>
###xml 168 176 <span type="species:ncbi:9606">patients</span>
These data demonstrate that BSCL2 plays an important role in the development of mature adipocytes and strongly suggest that the nearly global lack of adipose tissue in patients with BSCL2 mutations is a consequence of a cell-autonomous defect of adipogenesis. This provides the first mechanistic insight into how BSCL2 mutations cause severe lipodystrophy.
###end p 33
###begin title 34
Supplementary Material
###end title 34
###begin title 35
Online-Only Abstract
###end title 35
###begin p 36
This work was supported by funding from the British Heart Foundation (to J.J.R.); the Wellcome Trust (to V.A.P., R.K.S., and S.O.R.); the Medical Research Council (MRC), Institute of Metabolic Science (to S.V.) and Cambridge Institute of Medical Research (to N.G.); the European Union Framework 6 Diabesity Project (to A.T.); the Natural Sciences and Engineering Research Council Canada (to S.L.G.); the European Network on Functional Genomics of Type 2 Diabetes (EUGENE2) Consortium (to J.J.R. and S.O.R.); and the O. Arlotti Trust, Italy (to E.D.N.).
###end p 36
###begin p 37
Work was performed within the Institute of Metabolic Science Metabolic Research Laboratories, the National Institute for Health Research Cambridge Biomedical Research Centre, and the Medical Research Council Centre for the Study of Obesity and Related Metabolic Disorders. The authors are particularly grateful to Dr. Vladimir Saudek for helpful and insightful discussions.
###end p 37
###begin title 38
REFERENCES
###end title 38
###begin p 39
###xml 73 74 73 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 429 430 427 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 563 564 561 562 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 584 585 582 583 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 600 601 598 599 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 613 614 611 612 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 730 731 726 727 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 741 742 737 738 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 753 754 749 750 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 784 785 780 781 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 946 947 940 941 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1092 1093 1086 1087 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1105 1106 1099 1100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 1160 1161 1152 1153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1183 1184 1175 1176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 1256 1257 1248 1249 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1267 1268 1259 1260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 359 363 <span type="species:ncbi:10090">mice</span>
###xml 519 525 <span type="species:ncbi:10090">murine</span>
###xml 592 598 <span type="species:ncbi:10090">murine</span>
###xml 606 611 <span type="species:ncbi:9606">human</span>
###xml 867 871 <span type="species:ncbi:10090">mice</span>
###xml 1085 1090 <span type="species:ncbi:10090">mouse</span>
###xml 1098 1103 <span type="species:ncbi:9606">human</span>
###xml 1154 1158 <span type="species:ncbi:10090">mice</span>
BSCL2 expression in adipose tissue and developing and mature adipocytes. A: BSCL2 mRNA expression was determined by real-time PCR in subcutaneous (scW) and epididymal (epW) white adipose tissue, brown adipose tissue (BAT), brain (Brn), skeletal muscle (SkM), heart (Hrt), liver (Lvr), kidney (Kdy), lung (Lng), and spleen (Spln) isolated from 6-week-old male mice. Data are normalized to 18S RNA and represent the means +/- SEM (n = 4). BSCL2 mRNA expression was assayed by real-time PCR in differentiating cultures of murine embryonic stem cell embryoid bodies (B), C3H10T1/2 cells (C), and murine (D) or human (E) preadipocytes isolated from the stromovascular fraction of adipose tissue. Data represents means +/- SEM of four (B), three (C), or six (E) independent experiments. In D, data are means +/- SD obtained in two time courses with cells pooled from three mice in each case. *Statistically significant difference from values at day 0 (P < 0.05). BSCL2 mRNA expression was also determined in mature adipocyte (MAd) and stromovascular (SV) fractions from collagenase-digested mouse (F) or human (G) adipose tissue. Data are means +/- SEM from 5 mice (F) and 11 individuals (G). *Significant difference vs. expression in mature adipocyte fraction (P < 0.05). H: C3H10T1/2 cells stably transfected with myc-tagged wild-type BSCL2 were induced to differentiate for 6 days, permeablized with 0.05% saponin, and then fixed and immunostained with anti-myc (BSCL2) and anti-calnexin antibodies. Merged image shows overlay of the two proteins in which yellow indicates colocalization. White arrows indicate areas of colocalization, and the inset shows a close-up of one such area. Scale bar = 20 mum. (Please see  for a high-quality digital representation of this figure.)
###end p 39
###begin p 40
###xml 79 80 79 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 372 373 370 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 460 461 458 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 613 624 611 622 <italic xmlns:xlink="http://www.w3.org/1999/xlink">upper panel</italic>
###xml 648 659 646 657 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lower panel</italic>
###xml 723 724 721 722 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 764 765 762 763 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1071 1072 1067 1068 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
Effect of BSCL2 knockdown on adipogenesis in C3H10T1/2 pluripotent stem cells. A: BSCL2 mRNA was assayed by real-time PCR in C3H10T1/2 cells stably infected with a retrovirus generated with control shRNA vector (black bars) or BSCL2 targetting shRNA1 (dark gray bars) or shRNA2 (light gray bars). Values are normalized to cyclophilin A expression. Data are means +/- SEM (n = 4). *Statistically significant difference vs. control cells at the same time point. B: Control cells or cells expressing BSCL2 targetting shRNA1 or shRNA2 were differentiated for 8 days, and lipid accumulation was assessed by oil red O (upper panel) and light microscopy (lower panel). Expression of mRNA encoding adipocyte transcription factors (C) and mature adipocyte marker proteins (D) was assayed by real-time PCR in control cells at day 0 (white bars) and following differentiation for 8 days in control cells (black bars) or cells expressing BSCL2 targetting shRNA1 (dark gray bars) or shRNA2 (light gray bars). Values are normalized to cyclophilin A expression. Data are means +/- SEM (n = 4). *Statistically significant difference vs. control cells at day 8 (black bars). (Please see  for a high-quality digital representation of this figure.)
###end p 40
###begin p 41
###xml 411 412 393 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 430 431 408 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 490 491 466 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 578 579 554 555 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 644 645 620 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 658 659 634 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r2">2</xref>
###xml 1024 1025 989 990 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1037 1038 998 999 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1040 1041 1001 1002 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1053 1054 1014 1015 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1065 1066 1026 1027 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 1076 1077 1037 1038 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 1097 1098 1055 1056 <italic xmlns:xlink="http://www.w3.org/1999/xlink">I</italic>
###xml 1157 1158 1113 1114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
BSCL2 knockdown does not inhibit the induction of C/EBPbeta, C/EBPdelta C/EBPalpha, or PPARgamma but inhibits SREBP1c and lipogenic gene expression during early adipogenesis in C3H10T1/2 stem cells. Control cells (black bars) or cells expressing BSCL2 targetting shRNA1 (dark gray bars) or shRNA2 (light gray bars) were induced to differentiate for various times, and the expression of mRNA encoding C/EBPbeta (A) and C/EBPdelta (B) was determined by real-time PCR. Data are means +/- SEM (n = 4). *Statistically significant difference vs. control cells at the same time point. C: Control cells (c) or cells expressing BSCL2 targetting shRNA1 (1) or shRNA2 (2) were differentiated for various times and lysed, and samples were Western blotted to determine the expression of C/EBPbeta, C/EBPdelta, ETO, and calnexin as indicated. Control cells (black bars) or cells expressing BSCL2 targetting shRNA1 (dark gray bars) or shRNA2 (light gray bars) were induced to differentiate, and the expression of mRNA encoding C/EBPalpha (D), PPARgamma2 (E), SREBP1c (F), AGPAT2 (G), DGAT2 (H), and lipin 1beta (I) was determined by real-time PCR. Data are means +/- SEM (n = 4). *Statistically significant difference vs. control cells at the same time point. Data were normalized to cyclophilin A mRNA expression.
###end p 41
###begin p 42
###xml 61 62 61 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 445 450 445 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BSCL2</italic>
###xml 536 537 534 535 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 544 545 542 543 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 611 612 609 610 <italic xmlns:xlink="http://www.w3.org/1999/xlink">W</italic>
###xml 622 623 620 621 <italic xmlns:xlink="http://www.w3.org/1999/xlink">X</italic>
###xml 636 637 634 635 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 711 712 709 710 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 64 70 <span type="species:ncbi:10090">Murine</span>
###xml 163 168 <span type="species:ncbi:9606">human</span>
###xml 205 210 <span type="species:ncbi:9606">human</span>
###xml 439 444 <span type="species:ncbi:9606">human</span>
###xml 714 720 <span type="species:ncbi:10090">Murine</span>
###xml 780 785 <span type="species:ncbi:9606">human</span>
###xml 817 822 <span type="species:ncbi:9606">human</span>
Analysis of naturally occurring pathogenic mutants of BSCL2. A: Murine C3H10T1/2 pluripotent cells were transfected with empty vector (mock), myc-tagged wild-type human BSCL2 (WT), or myc-tagged wild-type human BSCL2 prematurely truncated at amino acid R275 (R275X) or bearing a point mutation causing amino acid substitution A212P. RNA was isolated 2 days posttransfection, DNase digested, and reverse transcribed before determination of human BSCL2 mRNA expression. Data are means +/- SEM normalized to cyclophilin A mRNA expression (n = 3). B: mock-transfected (m) cells or cells transfected with wild-type (W), R275X (X), or A212P (P) BSCL2 were lysed and samples Western blotted with an anti-myc antibody. C: Murine C3H10T1/2 cells were transfected with myc-tagged wild-type human BSCL2 (BSCL2-WT) or myc-tagged human BSCL2 A212P (BSCL2-A212P). Cells were fixed and immunostained with anti-myc antibodies. Scale bar = 20 mum. (Please see  for a high-quality digital representation of this figure.).
###end p 42

